SHPH

3.49010.51%
JM

J. Martin Brown

Member of Scientific Advisory Committee

Dr. J. Martin Brown, Ph.D., serves as Member of the Scientific Advisory Committee at Shuttle Pharmaceuticals Holdings, Inc since 2017. He serves as Scientific Advisor of Shuttle Pharmaceuticals for translational research for the development of hypoxic radiation sensitizers since 2017. Prof. Brown serves as Advisor of Proacta, Inc. Dr. Brown is a founder scientist of Proacta. He serves as a Professor in the Division of Radiation and Cancer Biology at Stanford University. He serves on the editorial boards of several scientific publications including Anticancer Research, Radiotherapy and Oncology, Cancer Letters, Molecular Cancer Therapeutics, Cancer Biology and Therapy and is the Senior Editor for Biology for the International Journal of Radiation Oncology, Biology and Physics. Prof. Brown is named as an inventor on 10 patents and is author/co-author of more than 250 scientific papers, and several books and conference proceedings. He has received awards in recognition of his work, including the Gold Medal, American Society for Therapeutic Radiology and Oncology (1999, the Failla Memorial Award, Radiation Research Society (2000), the Weiss Medal, Association for Radiation Research (2001) and the Henry S. Kaplan Distinguished Scientist Award, International Association for Radiation Research (2007). He developed etanidazole, a hypoxic radiation sensitizer, and tirapazamine, a hypoxic cytotoxic drug, from bench to clinical trials. He was Director of the Division of Radiation and Cancer Biology at Stanford University from 1984 to 2004. He is an expert in the radiation biology of hypoxia in cancers and has more than 300 peer-reviewed published articles. Dr. Brown received his Ph.D. in Cancer Biology from Oxford University in 1968.

Positions